BBNX
Beta Bionics, Inc.
Beta Bionics, Inc. (BBNX) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 63.4, with 1/3 trend checks passing.
BBNX with MA50 and MA200
Key levels & signals
Beta Bionics, Inc. (BBNX) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $16.86, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 26.7% and below the 200-day moving average by 5.7%.
BBNX currently has an RSI reading of 63.4, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.
This page is designed to help you quickly understand what the BBNX chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.
About Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Learn the indicators behind this page
More stock opportunities
Common questions about BBNX
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.